These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 23730844

  • 1. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.
    J Viral Hepat; 2013 Jul; 20(7):502-9. PubMed ID: 23730844
    [Abstract] [Full Text] [Related]

  • 2. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH.
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [Abstract] [Full Text] [Related]

  • 3. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG, Mohammed R, Yuen MF, Kao JH.
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [Abstract] [Full Text] [Related]

  • 4. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 5. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [Abstract] [Full Text] [Related]

  • 6. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals.
    Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK.
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00036. PubMed ID: 31107725
    [Abstract] [Full Text] [Related]

  • 7. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
    Hsu YC, Wu CY, Lane HY, Chang CY, Tai CM, Tseng CH, Lo GH, Perng DS, Lin JT, Mo LR.
    J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
    [Abstract] [Full Text] [Related]

  • 8. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti F, Primignani M, Jovani M, Iavarone M, Fraquelli M, Casazza G, de Franchis R, Colombo M.
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [Abstract] [Full Text] [Related]

  • 9. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

  • 10. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH, van Erpecum KJ, Schalm SW, Zaaijer HL, Brouwer JT, Gelderblom HC, de Knegt RJ, Minke Bakker C, Reesink HW, Janssen HL, Netherlands Association of Gastroenterologists and Hepatologists.
    Neth J Med; 2008 Jul; 66(7):292-306. PubMed ID: 18663260
    [Abstract] [Full Text] [Related]

  • 11. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis.
    Lin CW, Lin CC, Mo LR, Chang CY, Perng DS, Hsu CC, Lo GH, Chen YS, Yen YC, Hu JT, Yu ML, Lee PH, Lin JT, Yang SS.
    J Hepatol; 2013 Apr; 58(4):730-5. PubMed ID: 23220252
    [Abstract] [Full Text] [Related]

  • 12. Impact of HBV therapy on the incidence of hepatocellular carcinoma.
    Triolo M, Della Corte C, Colombo M.
    Liver Int; 2014 Feb; 34 Suppl 1():139-45. PubMed ID: 24373091
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical outcome of lamivudine-resistant chronic hepatitis B patients with compensated cirrhosis under adefovir salvage treatment. Importance of HCC surveillance.
    Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R.
    Eur J Intern Med; 2009 Sep; 20(5):478-81. PubMed ID: 19712848
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
    Leung N.
    Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.